We use cookies to enhance your browsing experience and analyze the performance of our website. By clicking Continue, you agree to the use of cookies. For more information, please see our Privacy Policy or update your Cookie Preferences.
Genova's Alzheimer's Assessment measures plasma p-Tau217, a specific protein identified as a reliable biomarker to aid in diagnosing Alzheimer's disease (AD).1 This assay helps detect AD pathology, including extracellular amyloid-beta plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau (p-tau), before the onset of clinical symptoms.
The Alzheimer's Assessment is intended for adult patients aged 45 and older who present with cognitive impairment and are being evaluated for AD or other causes of cognitive decline.
There are comorbid conditions that may affect phosphorylated tau levels in the blood. These can include conditions affecting hepatic and renal function, such as chronic kidney disease (CKD), as well as a history of stroke or myocardial infarction. Certain medications to support kidney function may also play a role in heightened levels of p-Tau217. Additionally, differences in results based on racial and ethnic background, sex, and age have not yet been established.
Genova's Alzheimer's Assessment measures plasma p-Tau217, a specific protein identified as a reliable biomarker to aid in diagnosing Alzheimer's disease (AD).1 This assay helps detect AD pathology, including extracellular amyloid-beta plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau (p-tau), before the onset of clinical symptoms.
The Alzheimer's Assessment is intended for adult patients aged 45 and older who present with cognitive impairment and are being evaluated for AD or other causes of cognitive decline.
There are comorbid conditions that may affect phosphorylated tau levels in the blood. These can include conditions affecting hepatic and renal function, such as chronic kidney disease (CKD), as well as a history of stroke or myocardial infarction. Certain medications to support kidney function may also play a role in heightened levels of p-Tau217. Additionally, differences in results based on racial and ethnic background, sex, and age have not yet been established.
